San Francisco, 4 February 2019: The Report Erectile Dysfunction Drugs Market Analysis By Product (Viagra, Levitra/Staxyn,
Stendra/Spedra, Zydena, Vitaros), And Segment Forecasts To 2022
The global erectile dysfunction drugs market is expected to reach USD 3.2 billion by 2022 according to a new report by Grand View Research Inc. Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this market.
However, the market is estimated to witness
decline in revenue over the forecast period. Expiration of key drugs from 2017
to 2019 is likely to curb revenue growth. On the other hand, the market is
likely to open up new avenues for the generic manufacturers to capitalize on. The
increasing risk of sexually transmitted diseases, narrowing of insurance
coverage for erectile dysfunction treatment, growing threat from counterfeit
drugs, and presence of social stigma in developing countries are some factors
limiting penetration rates.
Access Research Report of Erectile Dysfunction Drugs Market @ www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market
Further key findings from the report suggest:
· Viagra accounted for over 47.0% of the
total revenue in 2014. It is generally considered as the first line of treatment
for erectile dysfunction. Brand loyalty and advantages associated with this
drug such as high efficacy, and effectiveness are the major factors attributing
for its large market share.
· Cialis (tadalafil) from Eli Lilly & Co.
and Levitra (vardenafil) from Bayer AG are known to be the competitors for
Viagra globally. Cialis (tadalafil) was approved in 2003 by the U.S. FDA, as a
prescription drug in the U.S. Cialis is also known as “The Weekend Pill” owing
to its 36-hour effectiveness.
· After the patent expiration of key drugs
such as Cialis (tadalafil) in 2017 and Levitra (vardenafil) in 2018, other
drugs such as Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil
Cream) are expected to capture the market share during the forecasts period.
· North America constituted the largest share
of approximately 55.0% in 2013 of the total erectile dysfunction market.
Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the
U.S. till 2019 along with introduction of new erectile dysfunction drugs such
as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors
responsible for market growth during the forecasts period.
· Asia Pacific accounted for a revenue share
of over 16.5% in 2012 owing to the presence of a lucrative market for generic
drugs, untapped opportunities, and increasing awareness related to erectile
dysfunction in this region
· Apricus Biosciences Inc., Cristalia
Produtos Quimicos Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd.,
Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals
Co. Ltd., and Vivus, Inc. are some major players of this market
· Extensive R&D carried out by companies
and high unmet needs in developing economies are expected to boost industrial
growth. Key manufacturers are targeting regions with unmet clinical needs by
entering into agreement with local manufacturers and distributors. Key players
are constantly engaged in developing novel drugs in an attempt to improve the
presence and ensure sustainability.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global erectile dysfunction drugs market on the basis of product and region:
Erectile Dysfunction Drugs Product
Outlook (Revenue, USD Million, 2012 - 2022)
·
Viagra (sildenafil citrate)
·
Cialis (tadalafil)
·
Levitra/Staxyn (vardenafil)
·
Stendra/Spedra (avanafil)
·
Zydena (udenafil)
·
Vitaros (Alprostadil Cream)
·
Others
Erectile Dysfunction Drugs Regional
Outlook (Revenue, USD Million, 2012 - 2022)
·
North America
·
Europe
·
Asia Pacific
·
RoW
Access Press Release of
Erectile Dysfunction Drugs Market@ www.grandviewresearch.com/press-release/global-erectile-dysfunction-drugs-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment